MedPath

Effects of Prior Exposure to Conflicting Health Information on Responses to Subsequent Unrelated Health Messages

Not Applicable
Completed
Conditions
Communication Research
Interventions
Other: Exposure to conflicting health information
Other: No exposure to conflicting health information
Registration Number
NCT04247529
Lead Sponsor
University of Minnesota
Brief Summary

Many population-level public health strategies-including media campaigns and other behavioral interventions, screening recommendations, and vaccination policies-rely on messaging to promote cancer prevention and control. These strategies do not take place in a vacuum; rather, they occur in the context of a broader public information environment, which is increasingly characterized by conflicting and often controversial health information. Although studies have documented that such information is prevalent, a critical question remains unanswered: does exposure to conflicting health information in people's routine interactions with the broader information environment threaten the success of message-based population-level public health strategies? And, if so, who is most susceptible to the effects of such exposure? This study will provide a rigorous empirical test of these critical answered questions, guided by two specific aims: First, to evaluate whether prior exposure to conflicting health information influences responses to subsequent unrelated and uncontested health messages, a phenomenon that has been described as "carryover effects" (Primary Aim); and second, to identify whether there are individual-level differences in how conflict affects responses to these unrelated and uncontested health messages (Secondary Aim).

Detailed Description

To accomplish these aims, an online survey-based experiment using a population-based sample of U.S. adults (anticipated N=1,800) will be conducted. At 2 time points across a 28-day period, participants will be exposed to news stories and social media posts about 6 health topics: mammography screening, prostate-specific antigen (PSA) testing, Vitamin D supplementation, carbohydrate consumption, alcohol consumption, and breastfeeding. Participants will be randomized to 1 of 2 treatment groups that differ only in the amount of conflict presented in these news and social media posts (conflict, no conflict). At a third time point, after the exposure to conflict period, all participants will be exposed to 3 (out of a possible 9) messages from existing health campaigns about 3 behaviors for which there is scientific consensus: fruit and vegetable consumption, colorectal cancer screening, and physical activity. To assess carryover effects (Primary Aim), participants' receptivity to these messages-as measured through several affective and cognitive responses (e.g., confidence in the evidence presented)-will be measured. Message receptivity is expected to be lower among those who were randomized to receive conflicting health information. Individual-level differences in message receptivity are possible; thus exploratory analyses (Secondary Aim) will be conducted to assess whether carryover effects of exposure to conflict may be more pronounced among certain groups (e.g., those with greater trust in media sources, those of lower socioeconomic position).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
6046
Inclusion Criteria
  • 18+ U.S. adults
  • Members of NORC's AmeriSpeak Panel (https://amerispeak.norc.org/Pages/default.aspx)
  • Able to complete web-based survey
  • Able to read in English
Read More
Exclusion Criteria
  • None
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Exposure to conflictExposure to conflicting health information-
No exposure to conflictNo exposure to conflicting health information-
Primary Outcome Measures
NameTimeMethod
Negative affective responsesUp to 42 days

* Participants are asked to indicate how "the ad you just saw made you feel"

* 7 affective responses are randomly ordered: interested, frustrated, surprised, annoyed, distressed, optimistic, worried (response options: 1 "very slightly or not at all" to 5 "extremely")

Other negative cognitive responses to ad claimsUp to 42 days

• Participants are asked to indicate whether "the claims in the ad I just saw are" (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"): exaggerated, flawed, believable (reverse coded), reasonable (reverse coded)

CounterarguingUp to 42 days

• Participants are asked to indicate the extent to which they agree or disagree with 4 statements (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"):

* "I found myself agreeing with the ad" (reverse coded)

* "I thought of points that went against what the ad was saying"

* "I accepted the ad's claims" (reverse coded)

* "While reading the ad, I was skeptical of its claims"

Reactance/threat to freedomUp to 42 days

• Participants are asked to indicate the extent to which they agree or disagree with the following statement (response options: 1 "strongly disagree" to 5 "strongly agree"): "I felt like the ad was trying to manipulate me"

Perceived argument strengthUp to 42 days

• Participants are asked to indicate the extent to which they agree or disagree with 2 statements (randomly ordered; response options: 1 "strongly disagree" to 5 "strongly agree"):

* "The ad was convincing"

* "The ad gave me a strong reason to \[engage in the behavior specified in the ad\]"

Response efficacyUp to 42 days

• Participants are asked to respond to two items, presented in random order:

* "How confident are you that there is evidence to support the ad's claims?" (1 "not confident at all" to 7 "extremely confident")

* "How much do you think your health would benefit if you \[engaged in the behavior specified in the ad\]?" (1 "not at all" to 7 "extremely")

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

NORC at the University of Chicago (online only)

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath